Reuters logo
BRIEF-Infinity Pharmaceuticals reports phase 1 clinical and translational data for IPI-549
November 10, 2017 / 10:53 AM / 11 days ago

BRIEF-Infinity Pharmaceuticals reports phase 1 clinical and translational data for IPI-549

Nov 10 (Reuters) - Infinity Pharmaceuticals Inc

* ‍Reported phase 1 clinical and translational data for IPI-549, that targets immune-suppressive tumor macrophages​

* IPI-549 was well tolerated, demonstrated clinical activity, with 44 percent clinical benefit rate including one partial response​

* ‍Initial translational data from patient blood samples demonstrated that IPI-549 treatment results in immune stimulation​

* ‍For IPI-549, co expects to complete combination dose escalation and initiate combination expansion cohorts by end of 2017​

* There were no treatment-related serious adverse events or deaths from IPI-549 study​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below